Further studies are needed to investigate the possibility that CARM1 and METTL23 are involved in genetic diseases caused by lack of XPF activity and to approach anticancer drug resistance from the perspective of CARM1 and METTL23. This evidence concerns the gene ERCC4 and hereditary disease.